Keyphrases
MEK Inhibitor (MEKi)
100%
Preclinical Evaluation
100%
ACVR1
100%
Proteinase Inhibitor
100%
Bone Morphogenetic Protein
100%
Bone Morphogenetic Protein Signaling
40%
Pathway Inhibitors
30%
Activating mutation
20%
Tumor
20%
Mitogen-activated Protein Kinase
20%
Brain Penetrant
10%
E6201
10%
PD0325901
10%
Activin Receptor
10%
Phosphohistone H3
10%
Trial Experience
10%
Short-term Treatment
10%
Brainstem
10%
Natural History
10%
Clinically Significant
10%
Histone
10%
Melanoma
10%
Clinical Trials
10%
Combination Therapy
10%
Pathway Activation
10%
Standard of Care
10%
Therapeutic Target
10%
Response to Therapy
10%
Receptor Subtypes
10%
Gliomagenesis
10%
Clinical Trial Development
10%
Two-pathway
10%
Mouse Model
10%
Childhood Brain Tumors
10%
Diffuse Intrinsic Pontine Glioma
10%
Phase II Clinical Trial
10%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Inhibitor
100%
Mitogen Activated Protein Kinase Kinase Inhibitor
100%
Bone Morphogenetic Protein
100%
Clinical Trial
60%
Preclinical Study
40%
Mitogen Activated Protein Kinase
40%
Receptor
40%
Neoplasm
40%
Mouse Model
20%
Histone
20%
Pontine Glioma
20%
Activin A
20%
Melanoma
20%
Combination Therapy
20%
Serine
20%
Intracranial Tumor
20%
Diseases
20%
Medicine and Dentistry
MEK Inhibitor
100%
Protein Inhibitor
100%
Bone Morphogenetic Protein
100%
Clinical Trial
60%
Neoplasm
40%
Receptor
40%
Mitogen-Activated Protein Kinase
40%
Combination Therapy
20%
Pontine Glioma
20%
Histone
20%
Activin A
20%
Short Course Therapy
20%
Serine
20%
Brainstem
20%
Intracranial Tumor
20%
Melanoma
20%
Diseases
20%